Evoke Pharma, Inc. Stock News

Evoke PLC (LSE:EVOK) shares plummeted 18% after the William Hill owner reported annual results in line with expectations but revealed slower growth at the start of 2025.  Results for the past calendar year showed revenues up 3% to £1.75 billion and reported losses before tax more than tripling to £191.4 million from £65.2 million the previous year.

Evoke Pharma, Inc. (NASDAQ:EVOK ) Q4 2024 Earnings Conference Call March 13, 2025 4:30 PM ET Company Participants Daniel Kontoh-Boateng – DKB Partners Matt D'Onofrio – Chief Executive Officer Chris Quesenberry – Chief Commercial Officer, GIMOTI, EVERSANA Mark Kowieski – Chief Financial Officer Conference Call Participants Yale Jen – Laidlaw & Company Operator Good afternoon, and welcome to the ...

Q4 2024 revenue increased 24.6% over Q3 2024; Full-year 2024 revenue grew 97.8% year-over-year Strong growth in key commercial metrics, including prescriber base, fill rates, and patient enrollments Secured $14.3 million net proceeds in financings, ensuring Nasdaq compliance Presented compelling healthcare resource utilization data on GIMOTI at key gastroenterology conferences, including an awa...

SOLANA BEACH, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti® (metoclopramide) nasal spray, today announced that the Company is scheduled to release its fourth quarter and full year 2024 on Thursday, March 13, 2025, after the market closes.

SOLANA BEACH, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced the appointment of Greg Pyszczymuka to its Board of Directors, effective February 20, 2025. This marks the second board member app...

Expect shares in William Hill owner Evoke PLC to get off to a strong start when the market opens. That's because the bookmaker said full-year earnings for 2024 will surpass market expectations, with strong double-digit revenue growth in the fourth quarter driven by its online business.

FDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025 Gimoti remains only approved drug shown to reduce hospitalizations, emergency room and medical office visits and related costs compared to oral metoclopramide SOLANA BEACH, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused pri...

SOLANA BEACH, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that it has received notices of allowance for two U.S. patent applications by the United States Patent and Trademark Office, furth...